Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 4 , Pages 271-279 , July 2008

Basal forebrain atrophy is a presymptomatic marker for Alzheimer's disease

  • Andrew M. Hall

      Affiliations

    • Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    • ,
  • Robert Y. Moore

      Affiliations

    • Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    • Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    • ,
  • Oscar L. Lopez

      Affiliations

    • Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    • ,
  • Lewis Kuller

      Affiliations

    • Department of Neuroscience, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    • Department of Epidemiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    • ,
  • James T. Becker

      Affiliations

    • Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    • Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    • Department of Psychology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    • Corresponding Author InformationCorresponding author. Tel.: 412-246-6970; Fax: 412-246-6873.

References 

  1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–259
  2. Braak H, Rub U, Schultz C. Vulnerability of cortical neurons to Alzheimer's and Parkinson's diseases. K.DT. J Alzheimers Dis. 2006;9(Suppl):35–44
  3. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol (Berl). 2006;112:389–404
  4. Whitwell JL, Petersen R, Negash S, Weigand SD, Kantarci K, Ivnik RJ, et al. Patterns of atrophy differ among specifics subtypes of mild cognitive impairment. Arch Neurol. 2007;64:1130–1138
  5. Whitwell JL, Przybelski SA, Weigand SD, Knopman D, Boeve BF, Petersen R, et al. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain. 2007;130:1777–1786
  6. Kuller LH, Lopez OL, Newman A, Beauchamp NJ, Burke G, Dulberg C, et al. Risk factors for dementia in the cardiovascular health cognition study. Neuroepidemiology. 2003;22:13–22
  7. Lopez OL, Kuller LH, Fitzpatrick A, Ives D, Becker JT, Beauchamp N. Evaluations of dementia in the cardiovascular health cognition study. Neuroepidemiology. 2003;22:1–12
  8. Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognitive Study Part 1. Arch Neurol. 2003;60:1385–1389
  9. Ashburner J, Friston KJ. Voxel-based morphometry: the methods. Neurology. 2000;11:805–821
  10. Good CD, Johnsrude IS, Ashburner J, Henson RNA, Friston KJ, Frackowiak RSJ. A voxel-based morphometric study of aging in 465 normal adult human beings. NeuroImage. 2001;14(Pt 1):21–36
  11. Kuller LH, Shemanski L, Manolio T, Haan M, Fried L, Bryan N, et al. Relationship between ApoE, MRI findings, and cognitive function in the cardiovascular health study. Stroke. 1998;29:388–398
  12. Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York: The Psychological Corporation; 1981;
  13. Benton AL. The visual retention test as a constructional praxis task. Confin Neurol. 1967;29:1–16
  14. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) Examination. J Clin Psychiatry. 1987;48:314–318
  15. Lopez OL, Becker JT, Jagust WJ, Dulberg C, Fitzpatrick A, Kuller LH, et al. Neuropsychological characteristics of mild cognitive impairment subgroups. J Neurol Neurosurg Psychiatry. 2006;77:159–165
  16. Nelson HE. National Adult Reading Test. Windsor, England: NFER-Nelson; 1982;
  17. Raven JC. Coloured progressive matrices. Los Angeles, CA: Western Psychological Services; 1956;
  18. Delis DC, Kramer JH, Kaplan E, Ober BA. The California Verbal Learning Test. New York: Psychological Corporation; 1987;
  19. Saxton JA, Becker JT, Wisniewski S. The ROCF and dementia. In:  Knight JA editors. The handbook of Rey-Osterrieth complex figure usage: clinical and research applications. Lutz, FL: Psychological Assessment Resources, Inc; 2003;p. 569–582
  20. Huff FJ, Collins C, Corkin S, Rosen TJ. Equivalent forms of the Boston Naming Test. J Clin Exp Neuropsychol. 1986;8:556–562
  21. Benton AL. Differential behavioral effects in frontal lobe disease. Neuropsychologia. 1968;6:53–60
  22. Baddeley AD, Della Sala S, Papagno C, Spinnler H. Dual task performance in dysexecutive and non-dysexecutive patients with a frontal lesion. Neuropsychology. 1997;11:187–194
  23. Trenerry MR, Crosson B, DeBoe J, Leber WR. STROOP neuropsychological screening test. Odessa, FL: Psychological Assessment Resources; 1989;
  24. Reitan RM. Validity of the Trail Making test as an indicator of organic brain damage. Percep Mot Skills. 1958;8:271–276
  25. Klove H. Clinical neuropsychology. In:  Forster FM FM editors. The medical clinics of North America. New York: Saunders; 1963;
  26. Fahn S, Elton RI. UPDRS Development Committee: Unified Parkinsons Rating Scale. In:  Fahn S,  Marsden CD,  Caine D,  Goldstein M editor. Recent developments in Parkinson's disease. Florham Park, NJ: MacMillan Healthcare Information; 1987;p. 153–163
  27. Hachinski VC, Iliff LD, Zihka E, du Boulay GH, McAllister VL, Marshall J, et al. Cerebral blood flow in dementia. Arch Neurol. 1975;32:632–637
  28. Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, et al. Risk factors for 5-year mortality in older adults: the cardiovascular health study. JAMA. 1998;279:585–592
  29. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(Suppl 6):S10–S26
  30. McKhann G, Drachman DA, Folstein MF, Katzman R, Price DL, Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939–944
  31. Kawas C, Segal J, Stewart WF, Corrada M, Thal LJ. A validation study of the dementia questionnaire. Arch Neurol. 1994;51:901–906
  32. Jorm AF, Jacomb PA. The informant questionnaire on cognitive decline in the elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med. 1989;19:1015–1022
  33. Spears JR, Greer PJ, Ziolko SK, Aizenstein HJ, Carmichael O, Becker JT, et al. Evaluation of an age-specific neurological template. 2005;Presented at the Annual Meeting of the Organization of Human Brain Mapping. Toronto, Ontario, Canada; June
  34. Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol. 2000;47:430–439
  35. Killiany RJ, Hyman BT, Gomez-Isla T, Moss MB, Kikinis R, Jolesz F, et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology. 2002;58:1188–1196
  36. Jack CR, Petersen RC, Xu YC, Waring SC, O'Brien PC, Tangalos EG, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology. 1997;49:786–794
  37. Becker JT, Aizenstein H, Butters MA. Structural and functional neuroimaging findings in normal and pathological aging. In:  Bush SS,  Martin TA editor. Geriatric neuropsychology: fundamentals for practice. New York: Psychology Press; 2005;p. 141–164
  38. Jernigan TL, Salmon DP, Butters N, Hesselink JR. Cerebral structure on MRI: II—specific changes in Alzheimer's and Huntington's diseases. Biol Psychiatry. 1991;29:68–81
  39. Whitehouse P, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer's disease: evidence from selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981;10:122–126
  40. Selden N, Geula C, Hersh L, Mesulam MM. Human striatum: chemoarchitecture of the caudate nucleus, putamen and ventral striatum in health and Alzheimer's disease. Neuroscience. 1994;3:621–636
  41. Damasio H, Eslinger P, Damasio AR, Rizzo M, Huang K, Demeter S. Quantitative computed tomographic analysis in the diagnosis of dementia. Arch Neurol. 1989;40:715–719
  42. Baron JC, Chetelat G, Desgranges B, Perchey G, Landeau B, de la Sayette V, et al. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease. NeuroImage. 2001;14:298–309
  43. Karas GB, Scheltens P, Rombouts SARB, Visser PJ, van Schijndel RA, Fox NC, et al. Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. NeuroImage. 2004;23:708–716
  44. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In vivo measurement of activated microglia in dementia. Lancet. 2001;358:461–467
  45. Mintun MA, Larossa GN, Sheline YI, Denca CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented popoulation: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446–452
  46. Edison P, Archer A, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C] PIB and [18F] FDG PET study. Neurology. 2006;67:1–8
  47. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer's disease. Neurology. 2006;67:1575–1580
  48. Teipel SJ, Flatz WH, Heinsen H, Bokde AL, Schoenberg SO. Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain. 2005;128:2626–2644
  49. Braak H, Del Tredici K. Alzheimer's disease: intraneuronal alterations precede insoluble amyloid-beta formation. Neurobiol Aging. 2004;25:713–718
  50. Mesulam M, Shaw P, Mash D, Weinstraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continiuum. Ann Neurol. 2004;55:815–828
  51. Jack CR, Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397–1403
  52. Soininen HS, Partanen K, Pitkanen A, Vainio P, Hanninen T, Hallikanen M, et al. Volumetric MRI analysis of the amygdala and the hippocampua in subjects with age-associated memory impairment: correlation to visual and verbal memory. Neurology. 1994;44:1660–1668
  53. Du AT, Schuff N, Amend D, Laakso MP, Hsu YY, Jagust WJ, et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2001;71:441–447
  54. Visser PJ, Scheltens P, Verhey FRJ, Schmand B, Launer LJ, Jolles J, et al. Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol. 1999;246:477–485
  55. Pennanen C, Kivipelto M, Tuomainen S, Hartikainen P, Hanninen T, Laakso MP, et al. Hippocampus and entorhinal cortex in mild cogniitve impairment and early AD. Neurobiol Aging. 2004;25:303–310
  56. Becker JT, Davis SA, Hayaski KM, Meltzer CC, Thompson PM, Lopez OL, et al. Three-dimensional patterns of hippocampal atrophy in mild cognitive impairment. Arch Neurol. 2006;63:97–101
  57. Apostolova LG, Dinov ID, Dutton RA, Hayashi KM, Toga AW, Cummings JL, et al. 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease. Brain. 2006;129:2867–2873
  58. Rusinek H, Endo Y, De Santi S, Frid D, Tsui WH, Segal S, et al. Atrophy rate in medial temporal lobe during progression of Alzheimer disease. Neurology. 2004;63:2354–2359
  59. Jack CR, Petersen RC, Grundman M, Jin S, Gamst A, Ward CP, et al. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurbiol Aging. 2007;April 21; [Epublication ahead of print]
  60. Morris JC, Cummings J. Mild cognitive impairment (MCI) represents early-stage Alzheimer's disease. J Alz Dis. 2005;7:235–239
  61. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron J-C. Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. NeuroReport. 2002;13:1939–1943
  62. Bell-McGinty S, Lopez OL, Meltzer CC, Scanlon JM, Whyte EM, DeKosky ST, et al. Differential cortical atrophy in subgroups of mild cognitive impairment. Arch Neurol. 2005;62:1393–1397
  63. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron J-C. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology. 2003;60:1374–1377
  64. Chetelat G, Landeau B, Eustache F, Mezenge F, Viader F, de la Sayette V, et al. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. NeuroImage. 2005;27:934–946
  65. Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol. 2003;54:343–351
  66. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30:1104–1113
  67. Good CD, Scahill RT, Fox NC, Ashburner J, Friston KJ, Chan D, et al. Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. NeuroImage. 2001;17:29–46
  68. Ashburner J, Friston KJ. Why voxel-based morphometry should be used. Neuroimage. 2001;14:1238–1243
  69. Carmichael OT, Thompson PM, Dutton RA, Lu A, Lee SE, Lee JY, et al. Dementia-associated ventricular volume changes in a community cohort. NeuroImage. 2005;26(Suppl 1):S47
  70. Carmichael OT, Kuller LH, Lopez OL, Thompson PM, Dutton RA, Lee SE, et al. Ventricular volume and dementia progression in the Cardiovascular Health Study. Neurobiol Aging. 2007;28:389–397
  71. Wu M, Carmichael O, Lopez-Garcia P, Carter CS, Aizenstein HJ. Quantitative comparison of AIR, SPM, and the fully deformable model for atlas-based segmentation of functional and structural MR images. Hum Brain Mapp. 2006;27:747–754
  72. Aizenstein H, Stenger V. Regional brain activation during concurrent implicit and explicit sequence learning. Cereb Cortex. 2004;14:199–208
  73. Rosano C, Becker JT, Lopez OL, Lopez-Garcia P, Carter CS, Newman A, et al. Morphometric analysis of gray matter volume in demented older adults: exploratory analysis of the Cardiovascular Health Study Brain MRI database. Neuroepidemiology. 2005;24:221–229
  74. Carmichael O, Aizenstein HJ, Davis SW, Becker JT, Thompson PM, Meltzer CC, et al. Atlas-based hippocampus segmentation in Alzheimer's disease and mild cognitive impairment. NeuroImage. 2005;27:979–990
  75. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238–1248

PII: S1552-5260(08)00124-6

doi: 10.1016/j.jalz.2008.04.005

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 4 , Pages 271-279 , July 2008

Article Tools

* Image Usage & Resolution